Deal Watch: Immunocore Raises Biggest EU Financing, $320M, For TCR Biologics Program
Executive Summary
Celgene’s purchase of Receptos will add pipeline assets and help the biotech reach its end-of-decade revenue goals. Five Prime’s licensing deal with Inhibrx includes earn-outs for future “breakthrough therapy” designations.